Company news
Ribomic, Inc. news in 2021
Ribomic, Inc.'s news releases, calls and decks from 2021, newest first.
RIBOMIC Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration
December 28, 2021
RIBOMIC Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
December 23, 2021
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
November 15, 2021
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
November 15, 2021
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2021(Based on Japanese GAAP)
November 9, 2021
RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting
September 30, 2021
RIBOMIC Completes Patient Enrollment of its US Phase 2 Open-Label Extension Clinical Trial of RBM-007 for wet AMD (RAMEN Study)
August 30, 2021
RIBOMIC Completes Patient Enrollment of its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (TOFU Study)
August 4, 2021
RIBOMIC Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in treatment naive wet AMD Patients
July 12, 2021
RIBOMIC Announces Termination of MTA with The Pritzker Neuropsychiatric Disorders Research Consortium
May 28, 2021
Summary of Non-Consolidated Financial Results for the Year Ended March 31, 2021 (Based on Japanese GAAP)
May 25, 2021
RIBOMIC Announces Publication of Research Paper on Aptamer Drug Discovery for Achondroplasia
May 21, 2021
RIBOMIC Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR
May 21, 2021
RIBOMIC Announces Completion of its Phase I Trial of RBM-007 for the Treatment of Achondroplasia
May 21, 2021
Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31, 2020 (Based on Japanese GAAP)
February 24, 2021